Briefly tell us about your organization and areas of expertise.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Briefed as Snibe) is located in National Biological Industry Park (Shenzhen, China), founded in 1995. Since 1995, Snibe has focused on IVD field for 28 years and also become the first chemiluminescence immunoassay manufacturer in China who got FDA cleared. Now Snibe's products have covered more than 151 countries globally with installations of over 25,000 units. Moreover, Snibe provides one of the broadest chemiluminescence immunoassay test menus with 211 parameters, covering more than 22 test panels including thyroid, fertility, infectious disease, tumor markers and so on.

What do you think sets Asia apart from others when it comes to health, medical and laboratory innovation?

Asia is a potential research platform for the development of the healthcare industry. With the increasing demand for healthcare technology and solutions in the Asian region, its role in the global healthcare field is also becoming increasingly important. Snibe will continue to strive to provide high-quality in vitro diagnostic solutions and promote innovative development of in vitro diagnostic testing technology. Asia will be a vibrant and rapidly growing market.

Give us an insight into your portfolio and solutions, and the strategies your organization adopted to address the challenges of an evolving healthcare sector.

Snibe has been focused on chemiluminescence for many years. Snibe's Fully autoChemiluminescence Immunoassay (CLIA) System MAGLUMI X8 has ultra-speed throughput, which can reach up to 600 tests per hour. And Snibe also owns a broad CLIA test menu of up to 211 parameters, covering multiple disease programs. Meanwhile, Snibe is constantly expanding our product line. At present, Snibe has three main product lines: Immunoassay, Clinical chemistry and Molecular diagnosis, providing diversified total laboratory automation solutions.

What will you be showcasing at Medlab Asia 2023 and what opportunities are you looking forward to at the event?

At Medlab Asia 2023, Snibe will bring its highly anticipated CLIA products, the MAGLUMI X S series and one of the broadest CLIA test menus up to 211 parameters. In addition, Snibe will also bring new products from the clinical biochemistry and Molecular Diagnosis product lines, continuously providing customers with comprehensive clinical laboratory diagnostic solutions. We hope to communicate with more international partners and seize more market information and opportunities at Medlab Asia 2023.

Please highlight some of your recent achievements and accolades.

At Snibe, we're devoted to delivering top clinical diagnostic solutions and focus on the traceability of products. With certifications from multiple authoritative organizations, and active participation in esteemed quality assessment programs to meet the international standard, our commitment to excellence remains unwavering.

Tell us about your upcoming business plans in the pipeline.

Snibe will continue to pay attention to the needs of the international market, committed to providing high-quality and comprehensive in-vitro diagnostic services for global laboratories and promoting the development of the healthcare industry through efficient and accurate product performance. At the same time, Snibe will continue to be committed to the demand of the international market and hopes to enhance clinical laboratory technology exchanges in the international region and expand international scientific and technological exchanges and cooperation through Medlab Asia 2023.

Anything else you would like to add?

In the past 28 years, Snibe has focused on the field of chemiluminescence immunoassay, and created an independent research and development product ecology integrating "reagents, instruments, and raw materials". Snibe will firmly fulfill its corporate mission, customer-centric, market-oriented, and continuously promote the healthcare industry through continuous product and technological innovation. To be the pioneer in the global diagnosis field is our vision. Snibe's striving for excellence never ends.